Actively Recruiting
Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC
Led by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Updated on 2025-09-23
12
Participants Needed
1
Research Sites
267 weeks
Total Duration
On this page
Sponsors
S
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Lead Sponsor
O
Oncovir, Inc.
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this study is to evaluate the safety of a cancer peptide vaccine to prevent or delay acquired resistance in advanced ALK+ lung cancer patients currently on ALK targeted therapy.
CONDITIONS
Official Title
Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically or cytologically confirmed diagnosis of stage IV NSCLC or recurrent NSCLC not suitable for definitive multimodality therapy
- Documented ALK rearrangement detected by FISH, IHC, tissue NGS, or ctDNA NGS
- Currently treated with crizotinib, ceritinib, alectinib, brigatinib, or lorlatinib with stable disease for at least 4 months
- No known presence of specific ALK acquired resistance alterations targeted by the vaccine
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
- Male or female aged 18 years or older
You will not qualify if you...
- Known additional progressing malignancy or requiring active treatment within the past 3 years, except adequately treated non-melanoma skin cancer, in-situ disease, or other solid tumors treated with curative intent
- Cytotoxic chemotherapy within 14 days before or during study vaccine treatment
- Anti-neoplastic immunotherapy within 28 days before or during study vaccine treatment
- Systemic immune suppression including chronic oral or systemic steroids (topical or inhalational steroids allowed) or other relevant immune suppression
- Symptomatic central nervous system metastasis or asymptomatic CNS disease needing increased corticosteroids within 7 days before enrollment
- Current spinal cord compression detected by imaging (symptomatic or asymptomatic); leptomeningeal disease without cord compression allowed
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Johns Hopkins University
Baltimore, Maryland, United States, 21287
Actively Recruiting
Research Team
V
Vincent Lam, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here